专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2004063335A3 TNF-α BINDING MOLECULES 审中-公开
公开(公告)号：WO2004063335A3
公开(公告)日：2004-07-29
申请号：PCT/US2004/000290
申请日：2004-01-08
申请人： APPLIED MOLECULAR EVOLUTION , WATKINS, Jeffry, D. , VASSEROT, Alain, P. , MARQUIS, David , HUSE, William, D.
发明人： WATKINS, Jeffry, D. , VASSEROT, Alain, P. , MARQUIS, David , HUSE, William, D.
IPC分类号： A61K39/395 , C07K16/22
摘要： The present invention relates to TNF-α binding molecules and nucleic acid sequences encoding TNF-α binding molecules. In particular, the present invention relates to TNF-α binding molecules with a high binding affinity, a high association rate, a low dissociation rate with regard to human TNF-α and that are capable of neutralizing TNF-α at low concentrations. Preferably, the TNF-α binding molecules of the present invention comprise light and/or heavy chain variable regions with fully human frameworks (e.g. human germline frameworks).

2. 发明申请

WO2004103404A1 CD20 BINDING MOLECULES 审中-公开
标题翻译： CD20结合分子
公开(公告)号：WO2004103404A1
公开(公告)日：2004-12-02
申请号：PCT/US2004/015786
申请日：2004-05-20
申请人： APPLIED MOLECULAR EVOLUTION , WATKINS, Jeffry, D. , DAVIES, Julian , MARQUIS, David, M. , ALLAN, Barrett, W. , ONDEK, Brian
发明人： WATKINS, Jeffry, D. , DAVIES, Julian , MARQUIS, David, M. , ALLAN, Barrett, W. , ONDEK, Brian
IPC分类号： A61K39/395
CPC分类号： C07K16/2887 , A61K2039/505 , C07K2317/24 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/92
摘要： The present invention relates to CD20 binding molecules and nucleic acid sequences encoding CD20 binding molecules. In particular, the present invention relates to CD20 binding molecules with a high binding affinity, and a low dissociation rate, with regard to human CD20. Preferably, the CD20 binding molecules of the present invention comprise light and/or heavy chain variable regions with fully human frameworks (e.g. human germline frameworks).
摘要翻译：本发明涉及CD20结合分子和编码CD20结合分子的核酸序列。特别地，本发明涉及关于人CD20具有高结合亲和力和低解离速率的CD20结合分子。优选地，本发明的CD20结合分子包含具有完全人骨架（例如人种系框架）的轻链和/或重链可变区。

3. 发明申请

WO2004074455A2 Fc REGION VARIANTS 审中-公开
标题翻译： Fc区域变量
公开(公告)号：WO2004074455A2
公开(公告)日：2004-09-02
申请号：PCT/US2004/005112
申请日：2004-02-20
申请人： APPLIED MOLECULAR EVOLUTION , WATKINS, Jeffry, D. , ALLAN, Barrett
发明人： WATKINS, Jeffry, D. , ALLAN, Barrett
IPC分类号： C12N
CPC分类号： A61K39/395 , A61K2039/505 , C07K16/00 , C07K16/2896 , C07K2317/21 , C07K2317/52 , C07K2317/524 , C07K2317/72 , C07K2317/732
摘要： The present invention provides polypeptide Fc region variants and oligonucleotides encoding Fc region variants. Specifically, the present invention provides compositions comprising novel Fc region variants, methods for identifying useful Fc region variants, and methods for employing Fc region variants for treating disease.
摘要翻译：本发明提供多肽Fc区变体和编码Fc区变体的寡核苷酸。具体地，本发明提供包含新型Fc区变体的组合物，用于鉴定有用的Fc区变体的方法，以及使用Fc区变体用于治疗疾病的方法。

4. 发明申请

WO2004050041A2 BUTYRYLCHOLINESTERASE VARIANTS THAT ALTER THE ACTIVITY OF CHEMOTHERAPEUTIC AGENTS 审中-公开
标题翻译：化学治疗剂的活性的丁基胆碱酯酶变体
公开(公告)号：WO2004050041A2
公开(公告)日：2004-06-17
申请号：PCT/US2003/038684
申请日：2003-12-04
申请人： APPLIED MOLECULAR EVOLUTION, INC. , WATKINS, Jeffry, D. , PANCOOK, James, D.
发明人： WATKINS, Jeffry, D. , PANCOOK, James, D.
IPC分类号： A61K
CPC分类号： C12N9/18 , A61K38/00
摘要： The invention provides a butyrylchinesterase variant having the amino acid sequence selected from SEQ ID NOS: 4, 6, 8, 10, 12, 14, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194 and 196,, or functional fragment thereof. In addition, the invention provides a method of converting a camptothecin derivative to a topoisomerase inhibitor by contacting the camptothecin derivative with a butyrylcholinesterase variant selected from SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, and 196, or functional fragment thereof, under conditions that allow conversion of a camptothecin derivative to a topoisomerase inhibitor. Further, the invention provides a method of treating cancer by administering to an individual an effective amount of a butyrylcholinesterase variant selected from SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, and 196, or functional fragment thereof, exhibiting increased capability to convert a camptothecin derivative to a topoisomerase inhibitor compared to butyrylcholinesterase.
摘要翻译：本发明提供具有选自SEQ ID NO：4,6,8,10,12,14,24,26,28,30,32,34,36,38,40,42,44的氨基酸序列的丁酰基切割酶变体，46,48,50,52,54,56,58,60,62,64,66,68,70,72,74,76,78,80,82,84,86,88,90,92,94 ，96,98,100,102,104,106,108,110,112,114,116,118,120,122,124,126,128,130,132,134,136,138,140,142,144 ，146,148,150,152,154,156,158,160,162,164,166,168,170,172,174,176,178,180,182,184,186,188,190,192,194 和196 ,,或其功能片段。此外，本发明提供了一种通过使喜树碱衍生物与选自SEQ ID NO：2,4,6,8,10,12,14,26,26,26,26,26,26,26,26,26,26,26,26,26,28,26,26,26,26,26,26,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29 28，30，32，34，36，38，40，42，44，46，48，50，52，54，56，58，60，62，64，66，68，70， 78，80，82，84，86，88，90，92，94，96，98，100，102，104，106，108，110，112，114，116，118，120，122， 128，130，132，134，136，138，140，142，144，146，148，150，152，154，156，158，160，162，164， 178,180,182,184,186,188,190,192,194和196或其功能片段，在允许将喜树碱衍生物转化为拓扑异构酶抑制剂的条件下进行。此外，本发明提供了一种通过向个体施用有效量的丁酰胆碱酯酶变体来治疗癌症的方法，所述丁酰胆碱酯酶变体选自SEQ ID NO：2,4,6,8,10,12,14,24,26,28,30,40， 32,34,36,38,40,42,44,46,48,50,52,54,56,58,60,62,64,66,68,70,72,74,76,78,80,80， 82，84，86，88，90，92，94，96，98，100，102，104，106，108，110，112，114，116，118，120，122，124，126，128， 132,134,136,138,140,142,144,146,148,150,152,154,156,158,160,162,164,166,168,170,172,174,176,178,180， 182,184,186,188,190,192,194和196或其功能片段，与丁酰胆碱酯酶相比表现出增加将喜树碱衍生物转化为拓扑异构酶抑制剂的能力。

5. 发明申请

WO2002064796A3 BUTYRYLCHOLINESTERASE POLYPEPTIDE VARIANTS WITH INCREASED CATALYTIC EFFICIENCY AND METHODS OF USE 审中-公开
公开(公告)号：WO2002064796A3
公开(公告)日：2002-08-22
申请号：PCT/US2001/050450
申请日：2001-12-21
申请人： APPLIED MOLECULAR EVOLUTION, INC. , UNIVERSITY OF NEBRASKA MEDICAL CENTER , LOCKRIDGE, Oksana , WATKINS, Jeffry, D. , PANCOOK, James, D.
发明人： LOCKRIDGE, Oksana , WATKINS, Jeffry, D. , PANCOOK, James, D.
IPC分类号： C12N15/55
摘要： The invention provides twenty-five butyrylcholinesterase variants having increased cocaine hydrolysis activity as well as the corresponding encoding nucleic acids. The invention also provides libraries of butyrylcholinesterase variants as well as libraries of the corresponding nucleic acids encoding butyrylcholinesterase variants. The invention further provides methods of hydrolyzing a cocaine-based butyrylcholinesterase substrate as well as methods of treating a cocaine-induced condition.

6. 发明申请

WO2002064796A2 BUTYRYLCHOLINESTERASE POLYPEPTIDE VARIANTS WITH INCREASED CATALYTIC EFFICIENCY AND METHODS OF USE 审中-公开
标题翻译：具有增加的催化效率的丁基胆碱酯酶多肽变体及其使用方法
公开(公告)号：WO2002064796A2
公开(公告)日：2002-08-22
申请号：PCT/US2001/050450
申请日：2001-12-21
申请人： APPLIED MOLECULAR EVOLUTION, INC. , UNIVERSITY OF NEBRASKA MEDICAL CENTER , LOCKRIDGE, Oksana , WATKINS, Jeffry, D. , PANCOOK, James, D.
发明人： LOCKRIDGE, Oksana , WATKINS, Jeffry, D. , PANCOOK, James, D.
IPC分类号： C12N15/55
CPC分类号： C12Q1/46 , A61K38/00 , C12N9/18 , C12Y301/01008
摘要： The invention provides twenty-five butyrylcholinesterase variants having increased cocaine hydrolysis activity as well as the corresponding encoding nucleic acids. The invention also provides libraries of butyrylcholinesterase variants as well as libraries of the corresponding nucleic acids encoding butyrylcholinesterase variants. The invention further provides methods of hydrolyzing a cocaine-based butyrylcholinesterase substrate as well as methods of treating a cocaine-induced condition.
摘要翻译：本发明提供了具有增加的可卡因水解活性的二十五个丁酰胆碱酯酶变体以及相应的编码核酸。本发明还提供了丁酰胆碱酯酶变体的文库以及编码丁酰胆碱酯酶变体的相应核酸的文库。本发明还提供水解可卡因的丁酰胆碱酯酶底物的方法以及治疗可卡因诱导的病症的方法。

7. 发明申请

WO2003044036A1 TUMOR SPECIFIC MONOCLONAL ANTIBODIES 审中-公开
标题翻译：肿瘤特异性单克隆抗体
公开(公告)号：WO2003044036A1
公开(公告)日：2003-05-30
申请号：PCT/US2002/037134
申请日：2002-11-19
申请人： APPLIED MOLECULAR EVOLUTION, INC. , WATKINS, Jeffry, D.
发明人： WATKINS, Jeffry, D.
IPC分类号： C07H21/04
CPC分类号： C07K16/30 , A61K2039/505 , C07K2317/21 , C07K2317/55 , C07K2317/565 , C07K2317/77
摘要： The invention provides tumor-specific human monoclonal antibodies and functional fragments. Also provided are nucleic acids encoding tumor-specific human monoclonal antibodies and functional fragments. A method for reducing neoplastic cell proliferation is also provided. The method consists of administering an effective amount of a tumor-specific human monoclonal antibody or functional fragment. Also provided is a method of detecting a neoplastic cell in a sample. The method consists of contacting a cell with a tumor-specific monoclonal antibody or functional fragment and detecting the specific binding of the human monoclonal antibody or functional fragment to the sample.
摘要翻译：本发明提供肿瘤特异性人单克隆抗体和功能片段。还提供了编码肿瘤特异性人单克隆抗体和功能片段的核酸。还提供了减少肿瘤细胞增殖的方法。该方法包括施用有效量的肿瘤特异性人单克隆抗体或功能片段。还提供了检测样品中的肿瘤细胞的方法。该方法包括使细胞与肿瘤特异性单克隆抗体或功能片段接触，并检测人单克隆抗体或功能片段与样品的特异性结合。

8. 发明申请

WO2004092340A2 BUTYRYLCHOLINESTERASE VARIANT POLYPEPTIDES WITH INCREASED CATALYTIC EFFICIENCY AND METHODS OF USE 审中-公开
标题翻译：具有增加的催化效率的丁二烯基酯改性聚异戊二烯和使用方法
公开(公告)号：WO2004092340A2
公开(公告)日：2004-10-28
申请号：PCT/US2004/011225
申请日：2004-04-09
申请人： APPLIED MOLECULAR EVOLUTION, INC. , WATKINS, Jeffry, D. , PANCOOK, James, D.
发明人： WATKINS, Jeffry, D. , PANCOOK, James, D.
IPC分类号： C12N
CPC分类号： C12N9/18 , A61K38/00 , C12Y301/01008
摘要： The invention provides a butyrylcholinesterase variant having increased cocaine hydrolysis activity as well as the corresponding encoding nucleic acid. The invention further provides methods of hydrolyzing a cocaine-based butyrylcholinesterase substrate as well as methods of treating a cocaine-induced condition with the invention variant.
摘要翻译：本发明提供了具有增加的可卡因水解活性的丁酰胆碱酯酶变体以及相应的编码核酸。本发明还提供了水解可卡因类丁酰胆碱酯酶底物的方法以及用本发明变体治疗可卡因诱导病症的方法。

9. 发明申请

WO2012021249A2 INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF HISTIDYL-TRNA SYNTHETASES 审中-公开
标题翻译：创新发现与HISTIDYL-TRNA合成酶蛋白片段有关的治疗，诊断和抗体组合物
公开(公告)号：WO2012021249A2
公开(公告)日：2012-02-16
申请号：PCT/US2011/043758
申请日：2011-07-12
申请人： ATYR PHARMA, INC. , PANGU BIOPHARMA LIMITED , GREENE, Leslie, Ann , CHIANG, Kyle, P. , HONG, Fei , VASSEROT, Alain, P. , LO, Wing-Sze , WATKINS, Jeffry, D. , QUINN, Cheryl, L. , MENDLEIN, John, D.
发明人： GREENE, Leslie, Ann , CHIANG, Kyle, P. , HONG, Fei , VASSEROT, Alain, P. , LO, Wing-Sze , WATKINS, Jeffry, D. , QUINN, Cheryl, L. , MENDLEIN, John, D.
IPC分类号： A61K38/16 , A61K38/10 , A61K38/08 , A61K39/395 , A61P35/00 , A61P3/10 , A61P3/00
CPC分类号： C12N9/93 , A61K38/00 , A61K38/53 , C07K16/40 , C12N5/0602 , C12N9/96 , C12Y601/01 , C12Y601/01021 , G01N33/68
摘要： Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
摘要翻译：提供了包含氨酰基-tRNA合成酶的新鉴定的蛋白片段，编码它们的多核苷酸及其互补物的组合物，相关试剂及其在诊断，药物开发，研究和治疗应用中的使用方法。

10. 发明申请

WO2011153277A2 INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF LYSYL-TRNA SYNTHETASES 审中-公开
标题翻译：与LYSYL-TRNA合成蛋白片段相关的治疗，诊断和抗体组合物的创新发现
公开(公告)号：WO2011153277A2
公开(公告)日：2011-12-08
申请号：PCT/US2011/038813
申请日：2011-06-01
申请人： ATYR PHARMA, INC. , PANGU BIOPHARMA LIMITED , GREENE, Leslie, Ann , CHIANG, Kyle, P. , HONG, Fei , VASSEROT, Alain, P. , LO, Wing-Sze , WATKINS, Jeffry, D. , QUINN, Cheryl, L. , MENDLEIN, John, D.
发明人： GREENE, Leslie, Ann , CHIANG, Kyle, P. , HONG, Fei , VASSEROT, Alain, P. , LO, Wing-Sze , WATKINS, Jeffry, D. , QUINN, Cheryl, L. , MENDLEIN, John, D.
IPC分类号： A61K38/16 , A61K38/08 , A61K38/17 , A61K39/395 , A61P37/00 , A61P21/00
CPC分类号： C07K16/40 , A61K38/00 , C07K2317/24 , C07K2317/622 , C12N5/0602 , C12N9/93 , C12N9/96 , C12Y601/01 , C12Y601/01007 , G01N33/573 , G01N33/68 , G01N2333/9015
摘要： Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
摘要翻译：提供了包含新确定的氨酰-tRNA合成酶的蛋白质片段的组合物，编码它们的多核苷酸及其补体，相关试剂及其在诊断，药物发现，研究和治疗应用中的使用方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式